QQQ   275.95 (-0.45%)
AAPL   114.09 (-0.76%)
MSFT   207.26 (-1.04%)
FB   261.79 (+1.94%)
GOOGL   1,466.02 (+0.50%)
AMZN   3,144.88 (-0.92%)
TSLA   419.07 (-0.51%)
NVDA   529.03 (+1.46%)
BABA   276.93 (+0.33%)
CGC   14.50 (+2.04%)
GE   6.12 (-1.29%)
MU   50.71 (+1.99%)
AMD   81.77 (+2.88%)
T   28.30 (-0.28%)
F   6.60 (-1.35%)
ACB   4.68 (-2.09%)
GILD   62.10 (-1.19%)
NFLX   493.48 (+0.58%)
DIS   125.40 (-0.47%)
BA   163.60 (-1.49%)
BAC   23.77 (-1.33%)
QQQ   275.95 (-0.45%)
AAPL   114.09 (-0.76%)
MSFT   207.26 (-1.04%)
FB   261.79 (+1.94%)
GOOGL   1,466.02 (+0.50%)
AMZN   3,144.88 (-0.92%)
TSLA   419.07 (-0.51%)
NVDA   529.03 (+1.46%)
BABA   276.93 (+0.33%)
CGC   14.50 (+2.04%)
GE   6.12 (-1.29%)
MU   50.71 (+1.99%)
AMD   81.77 (+2.88%)
T   28.30 (-0.28%)
F   6.60 (-1.35%)
ACB   4.68 (-2.09%)
GILD   62.10 (-1.19%)
NFLX   493.48 (+0.58%)
DIS   125.40 (-0.47%)
BA   163.60 (-1.49%)
BAC   23.77 (-1.33%)
QQQ   275.95 (-0.45%)
AAPL   114.09 (-0.76%)
MSFT   207.26 (-1.04%)
FB   261.79 (+1.94%)
GOOGL   1,466.02 (+0.50%)
AMZN   3,144.88 (-0.92%)
TSLA   419.07 (-0.51%)
NVDA   529.03 (+1.46%)
BABA   276.93 (+0.33%)
CGC   14.50 (+2.04%)
GE   6.12 (-1.29%)
MU   50.71 (+1.99%)
AMD   81.77 (+2.88%)
T   28.30 (-0.28%)
F   6.60 (-1.35%)
ACB   4.68 (-2.09%)
GILD   62.10 (-1.19%)
NFLX   493.48 (+0.58%)
DIS   125.40 (-0.47%)
BA   163.60 (-1.49%)
BAC   23.77 (-1.33%)
QQQ   275.95 (-0.45%)
AAPL   114.09 (-0.76%)
MSFT   207.26 (-1.04%)
FB   261.79 (+1.94%)
GOOGL   1,466.02 (+0.50%)
AMZN   3,144.88 (-0.92%)
TSLA   419.07 (-0.51%)
NVDA   529.03 (+1.46%)
BABA   276.93 (+0.33%)
CGC   14.50 (+2.04%)
GE   6.12 (-1.29%)
MU   50.71 (+1.99%)
AMD   81.77 (+2.88%)
T   28.30 (-0.28%)
F   6.60 (-1.35%)
ACB   4.68 (-2.09%)
GILD   62.10 (-1.19%)
NFLX   493.48 (+0.58%)
DIS   125.40 (-0.47%)
BA   163.60 (-1.49%)
BAC   23.77 (-1.33%)
Log in
NASDAQ:BWAY

BRAINSWAY LTD/S Stock Forecast, Price & News

$5.90
-0.02 (-0.34 %)
(As of 09/29/2020 12:00 AM ET)
Add
Compare
Today's Range
$5.81
Now: $5.90
$5.90
50-Day Range
$5.63
MA: $6.56
$8.00
52-Week Range
$5.10
Now: $5.90
$12.53
Volume2,702 shs
Average Volume14,704 shs
Market Capitalization$63.84 million
P/E RatioN/A
Dividend YieldN/A
Beta1.14
Brainsway Ltd. engages in the development and provision of technology solutions for non-invasive treatment of brain disorders in Israel and internationally. It offers deep transcranial magnetic stimulation systems for treating various conditions, including autism, Alzheimer's disease, bipolar disorders, chronic pains, depressive disorders, Parkinson's diseases, schizophrenia, smoking cessation, post-traumatic stress disorders, multiple sclerosis, obsessive compulsive disorders, and stroke rehabilitation. Brainsway Ltd. was founded in 2003 and is based in Jerusalem, Israel.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.35 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BWAY
CUSIPN/A
CIKN/A
Phone972-2581-3140

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$23.10 million
Book Value$2.24 per share

Profitability

Net Income$-10,330,000.00

Miscellaneous

Employees96
Market Cap$63.84 million
Next Earnings Date11/23/2020 (Estimated)
OptionableNot Optionable
$5.90
-0.02 (-0.34 %)
(As of 09/29/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BWAY News and Ratings via Email

Sign-up to receive the latest news and ratings for BWAY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











BRAINSWAY LTD/S (NASDAQ:BWAY) Frequently Asked Questions

How has BRAINSWAY LTD/S's stock price been impacted by Coronavirus (COVID-19)?

BRAINSWAY LTD/S's stock was trading at $8.19 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, BWAY shares have decreased by 28.0% and is now trading at $5.90.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of BRAINSWAY LTD/S?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BRAINSWAY LTD/S in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for BRAINSWAY LTD/S
.

When is BRAINSWAY LTD/S's next earnings date?

BRAINSWAY LTD/S is scheduled to release its next quarterly earnings announcement on Monday, November 23rd 2020.
View our earnings forecast for BRAINSWAY LTD/S
.

How were BRAINSWAY LTD/S's earnings last quarter?

BRAINSWAY LTD/S (NASDAQ:BWAY) issued its earnings results on Wednesday, August, 12th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.12) by $0.09. The business had revenue of $4.82 million for the quarter, compared to the consensus estimate of $4.70 million. BRAINSWAY LTD/S had a negative return on equity of 38.87% and a negative net margin of 42.27%.
View BRAINSWAY LTD/S's earnings history
.

What price target have analysts set for BWAY?

3 brokerages have issued 12 month price targets for BRAINSWAY LTD/S's shares. Their forecasts range from $9.00 to $13.00. On average, they expect BRAINSWAY LTD/S's stock price to reach $11.67 in the next year. This suggests a possible upside of 97.7% from the stock's current price.
View analysts' price targets for BRAINSWAY LTD/S
.

Are investors shorting BRAINSWAY LTD/S?

BRAINSWAY LTD/S saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 31,200 shares, an increase of 34.5% from the August 31st total of 23,200 shares. Based on an average trading volume of 24,000 shares, the days-to-cover ratio is presently 1.3 days.
View BRAINSWAY LTD/S's Short Interest
.

Who are some of BRAINSWAY LTD/S's key competitors?

What other stocks do shareholders of BRAINSWAY LTD/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BRAINSWAY LTD/S investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), Enterprise Products Partners (EPD), Pfizer (PFE), Boingo Wireless (WIFI), Ampio Pharmaceuticals (AMPE), Eastman Chemical (EMN), Enbridge (ENB), Energy Transfer LP Unit (ET) and Gilead Sciences (GILD).

Who are BRAINSWAY LTD/S's key executives?

BRAINSWAY LTD/S's management team includes the following people:
  • Dr. David Zacut, Founder & Chairman (Age 66)
  • Prof. Abraham Zangen, Founder & Member of the Scientific Advisory Board (Age 49)
  • Dr. Yiftach Roth, Founder & Chief Scientist (Age 48)
  • Mr. Hadar Levy, Chief Financial Officer (Age 45)
  • Mr. Ronen Segal, Chief Technology Officer (Age 46)

When did BRAINSWAY LTD/S IPO?

(BWAY) raised $30 million in an initial public offering (IPO) on Wednesday, April 17th 2019. The company issued 2,500,000 shares at $11.94 per share. Cantor acted as the underwriter for the IPO.

What is BRAINSWAY LTD/S's stock symbol?

BRAINSWAY LTD/S trades on the NASDAQ under the ticker symbol "BWAY."

How do I buy shares of BRAINSWAY LTD/S?

Shares of BWAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BRAINSWAY LTD/S's stock price today?

One share of BWAY stock can currently be purchased for approximately $5.90.

How big of a company is BRAINSWAY LTD/S?

BRAINSWAY LTD/S has a market capitalization of $63.84 million and generates $23.10 million in revenue each year. The company earns $-10,330,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. BRAINSWAY LTD/S employs 96 workers across the globe.

What is BRAINSWAY LTD/S's official website?

The official website for BRAINSWAY LTD/S is www.brainsway.com.

How can I contact BRAINSWAY LTD/S?

BRAINSWAY LTD/S's mailing address is 19 HARTUM STREET BYNET BUILDING 3RD FL Har HaHotzvim, Jerusalem L3, 9777518. The company can be reached via phone at 972-2581-3140 or via email at [email protected]

This page was last updated on 9/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.